Filing Details

Accession Number:
0000899243-21-046974
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-06 17:34:52
Reporting Period:
2021-12-02
Accepted Time:
2021-12-06 17:34:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1832415 Better Therapeutics Inc. BTTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1547557 J Kevin Appelbaum C/O Better Therapeutics, Inc.
548 Market Street, #49404
San Francisco CA 94104
Chief Executive Officer Yes Yes Yes No
1890904 Kevin Appelbaum, Or His Successor(S), As Trustee Of The Kevin Appelbaum Revocable Trust Under Revocable Trust Declaration Dated 5/16/2020, As Amended C/O Better Therapeutics, Inc.
548 Market Street, #49404
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-02 500 $6.84 500 No 4 P Direct
Common Stock Acquisiton 2021-12-03 500 $6.43 1,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,406,719 Indirect By Trust
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.440 to $6.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.